Skip to Content

Rocuronium Disease Interactions

There are 10 disease interactions with rocuronium:

Major

Neuromuscular Blocking Agents (Includes Rocuronium) ↔ Burns

Severe Potential Hazard, Moderate plausibility

Applies to: Burns - External

Patients with burns may develop resistance to non-depolarizing neuromuscular blocking agents. These patients may experience a shorter duration of action and/or require higher dosages of the drugs. The extent of altered response depends on the duration since and the size of the burn.

References

  1. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  2. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  3. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
Major

Neuromuscular Blocking Agents (Includes Rocuronium) ↔ Electrolyte Imbalance

Severe Potential Hazard, Moderate plausibility

Applies to: Electrolyte Abnormalities

Severe acid-base and/or electrolyte abnormalities may potentiate or cause resistance to the neuromuscular blocking action neuromuscular blocking agents. The potency of these agents may be mixed in metabolic acidosis and alkalosis, and in respiratory alkalosis. Since electrolyte imbalance and acid-base imbalance are usually mixed, either enhancement or inhibition may occur. Caution should be taken when using these agents in predisposed patients.

References

  1. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
  2. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
Major

Neuromuscular Blocking Agents (Includes Rocuronium) ↔ Histamine Release

Severe Potential Hazard, Moderate plausibility

Applies to: Allergies, Asthma, Cardiovascular Disease

Some neuromuscular blocking agents stimulate the release of histamine, which can cause wheezing, bronchospasm, increased bronchial secretions, hypotension, tachycardia, and circulatory collapse. Hypotension may also occur due to ganglionic blockade or as a complication of positive pressure respiration. Tubocurarine appears to be the most potent inducer of histamine, followed by metocurine (no longer commercially available in the U.S.) and succinylcholine. Other agents with varying but lesser degrees of histamine-releasing properties include atracurium, mivacurium, and pancuronium (at excessive dosages). Therapy with these neuromuscular blocking agents should be administered cautiously in patients with clinically significant cardiovascular disease and/or a history of asthma or severe allergic reactions. Certain agents may prolong the QTc interval, specially during general anesthesia in pediatric patients. The initial dosage and rate of administration may need to be reduced, and hemodynamic and respiratory status carefully monitored. Neuromuscular blocking agents that appear to have little or no histamine-inducing effects include cisatracurium, doxacurium, pipecuronium, rocuronium, and vecuronium.

References

  1. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  2. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  3. "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.
View all 7 references
Major

Neuromuscular Blocking Agents (Includes Rocuronium) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

Neuromuscular blocking agents undergo metabolism by the liver. Elimination and effects may be prolonged in patients with liver disease. Therapy with neuromuscular blocking agents should be administered cautiously in patients with liver disease.

References

  1. "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.
  2. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
  3. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
View all 5 references
Major

Neuromuscular Blocking Agents (Includes Rocuronium) ↔ Myasthenia Gravis

Severe Potential Hazard, Moderate plausibility

Applies to: Myasthenia Gravis

The use of neuromuscular blocking agents may cause prolonged respiratory paralysis. Therapy with neuromuscular blocking agents should be administered cautiously in patients with myasthenia gravis. Use of a peripheral nerve stimulator may be helpful in evaluating the level of neuromuscular blockade.

References

  1. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  2. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
  3. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
View all 4 references
Major

Neuromuscular Blocking Agents (Includes Rocuronium) ↔ Paresis

Severe Potential Hazard, High plausibility

Applies to: Paralytic Disorder

Patients with hemiparesis or paraparesis may require higher dosages of non-depolarizing neuromuscular blocking agents in the affected limbs. Neuromuscular monitoring should be performed on a non-paretic limb to avoid inaccurate dosing.

References

  1. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  2. "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.
  3. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
View all 6 references
Major

Neuromuscular Blocking Agents (Includes Rocuronium) ↔ Pulmonary Impair

Severe Potential Hazard, High plausibility

Applies to: Pulmonary Impairment

Neuromuscular blocking agents can cause respiratory depression and paralysis. Therapy with neuromuscular blocking agents should be administered cautiously in patients with pulmonary impairment. Treatment of respiratory paralysis consists of positive-pressure artificial respiration with oxygen and maintenance of a patent airway until the recovery of normal respiration is assured.

References

  1. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  2. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  3. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
View all 7 references
Moderate

Neuromuscular Blocking Agents (Includes Rocuronium) ↔ Cachexia

Moderate Potential Hazard, Moderate plausibility

Applies to: Cachexia, Malnourished

Nondepolarizing neuromuscular blocking agents have been found to exhibit profound neuromuscular blocking effects in cachectic or debilitated patients, patients with neuromuscular diseases, and patients with carcinomatosis. In these or other patients in whom potentiation of neuromuscular block or difficulty with reversal may be anticipated, a decrease from the recommended initial dose of should be considered.

Moderate

Neuromuscular Blocking Agents (Includes Rocuronium) ↔ Seizures

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures, Cerebral Palsy - Infantile

Resistance to nondepolarizing agents, consistent with up-regulation of skeletal muscle acetylcholine receptors, is associated with burns, disuse atrophy, denervation, and direct muscle trauma. Receptor up-regulation may also contribute to the resistance to nondepolarizing muscle relaxants which sometimes develops in patients with cerebral palsy, patients chronically receiving anticonvulsant agents. When a neuromuscular blocking agents is administered to these patients, shorter durations of neuromuscular block may occur, and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. Caution is advisable when using these agents.

Moderate

Rocuronium (Includes Rocuronium) ↔ Malignant Hyperthermia

Moderate Potential Hazard, Moderate plausibility

Applies to: Malignant Hyperthermia

Because rocuronium bromide is always used with other agents, and the occurrence of malignant hyperthermia during anesthesia is possible even in the absence of known triggering agents, clinicians should be familiar with early signs, confirmatory diagnosis, and treatment of malignant hyperthermia prior to the start of any anesthetic agent. Care should be taken when using this agent.

rocuronium drug Interactions

There are 271 drug interactions with rocuronium

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide